Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

270

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions

IPF and PPF

Interventions

DRUG

HRS-9813 capsules

HRS-9813 capsule; High dose

DRUG

HRS-9813 capsules

HRS-9813 capsule; Low dose

DRUG

HRS-9813 capsule mimetic

Trial Locations (1)

Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY